Unlike alcohol and nicotine, there is no FDA-approved pharmacological treatment for cocaine use disorder (CoCUD). The purpose of this study was to investigate clavulanic acid (CLAV), a GLT-1 activator, for its potential to treat CoCUD. Resting state fMRI was used to assess changes in the anterior cingulate cortex (ACC) functional connectivity with repeated CLAV for 10 days. CLAV altered the connectivity of ACC with default mode network, motor control, and addiction cue reactivity related regions. This pilot study supports the development of CLAV for CoCUD treatment.